Navigation Links
NeuroVive Admitted to Trading on NASDAQ OMX Stockholm

LUND, Sweden, March 25, 2013 /PRNewswire/ --

NeuroVive, a leading mitochondrial medicine company, announces that its shares have been approved for listing on NASDAQ OMX Stockholm by the exchange's Listing Committee. The first day of trading on NASDAQ OMX Stockholm will be April 10th and the last day of trading on the Swedish trading platform AktieTorget will be April 9th.

The stock will be traded under the same ticker symbol, NVP. No new shares will be issued in conjunction with the listing on NASDAQ OMX Stockholm.

Mikael Bronnegard, CEO of NeuroVive Pharmaceutical said: "Our move to NASDAQ OMX Stockholm is an important step forward in the growth and development of our company. Through this listing NeuroVive will gain access to a broader and deeper pool of investors that will be vital as we look to finance our strategy which is designed to maximize shareholder value from our leading position in mitochondrial medicine."

About NeuroVive Pharmaceutical AB (publ)

NeuroVive Pharmaceutical AB ( a leading mitochondrial medicine company is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection.

NeuroVive's products are based on the cyclophilin inhibitor, cyclosporine, and work by preventing the death of mitochondria in distressed cells and the subsequent cascade of intracellular biochemical events that lead to secondary tissue damage following an acute cardiac or traumatic brain injury.

NeuroVive's lead product is CicloMulsion®, the first cyclophilin inhibitor for the treatment of reperfusion injuries following cardiac stenting. CicloMulsion® is currently in a 1000 patient Phase III clinical trial evaluating its ability to reduce reperfusion injuries in patients with myocardial infarction.

NeuroVive is also developing NeuroSTAT®, a cyclophilin inhibitor, which is entering a Phase IIa clinical trial in patients with severe traumatic brain injury. Both indications have huge medical need and for which there are currently no approved pharmaceutical treatment options. Both CicloMulsion® and NeuroSTAT® are special formulations of cyclosporine for use in acute cardiac and brain injury indications.

NeuroVive's pipeline includes novel cyclophilin inhibitors, and drug candidates that act on mitochondria to address energy regulation disorders.

NeuroVive´s shares are listed on the Swedish trading platform AktieTorget ( The AktieTorget market is focused on emerging, entrepreneurial businesses through an electronic trading system supplied by the OMX Nordic stock exchange in Stockholm, Sweden.

Media and investor relations contacts
NeuroVive Pharmaceutical: Mikael Bronnegard
Phone No: +46(0)70-299-62-64

Citigate Dewe Rogerson: Nina Enegren / David Dible
Phone No: +44(0)207-282-1050

SOURCE NeuroVive
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroVive Acquires Highly Potent, Novel Cyclophilin Inhibitors From Biotica
2. NeuroVive Appoints Chief Operating Officer
3. Sihuan Pharmaceutical Collaborates with NeuroVive to Develop Two Innovative Cardio-cerebral Vascular Products in China
4. PAREXEL International Provides Update On Share Repurchase Program, Announces A New $50 Million Accelerated Share Repurchase Agreement And A New $50 Million 10b5-1 Trading Plan
5. Trading of Depomed Common Stock Halted
6. Vasomedical Common Stock Commences Trading on the OTCBB
7. MetaStat Announces Stock Trading on OTC Bulletin Board
8. SafeCode Drug Technologies Corp. Begins Trading on the Over-the-Counter Bulletin Board
9. Generex Addresses Recent Trading Volume in Shares of its Common Stock
10. Sae-A Trading Sponsors Medical Mission to Haiti
11. Angeion Announces Name Change and New Trading Symbol Effective Tuesday, August 21, 2012
Post Your Comments:
(Date:11/24/2015)... F1000Workspace - a research collaboration, reference management and ... six months ago. --> F1000Workspace - a ... since it was launched just six months ago. --> ... F1000Workspace - a research collaboration, reference management and authoring ... months ago. --> --> ...
(Date:11/24/2015)... , Nov. 24, 2015  Family Rentals, ... recently announced the launch of their newly designed, ... --> --> ... --> --> Now, renting ... travel and vacation, just got a whole lot ...
(Date:11/24/2015)... Pa. , Nov. 24, 2015  NuShield, Inc., an industry leader in LCD screen protection ... and stationary computer technology as part of their patient monitoring or electronic documentation system. ... ... ... A ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... There’s nothing better than giving the ... all levels can enjoy. , This year, gardens are popping up in the ... living needs. , Vita Gardens’ African Keyhole Garden Bed ($499) , Water conscious ...
(Date:11/24/2015)... ... 24, 2015 , ... Wireless Analytics, an award-winning provider of ... weekday support capability. The “all hours” offering was introduced to extend live ... to enhance after-hours support available in the US. , Available as one of ...
(Date:11/24/2015)... ... 2015 , ... Take the audience on a journey with TransFrame Cloud from Pixel ... of images without ever setting a single keyframe in Final Cut Pro X. Design smooth ... controls to change the angle and depth of field to create a unique viewing perspective. ...
(Date:11/24/2015)... ... November 24, 2015 , ... Tuesday, December 1, 2015 Push to Walk ... letters to its supporters as part of their A Little Push Goes a Long ... giving where people are asked to support charities and non-profits on the Tuesday following ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... United States has performed a prostate tissue ablation procedure using the company’s ... on October 9, 2015. , This Sonablate® procedure, the first commercial focused ultrasound ...
Breaking Medicine News(10 mins):